Publikationen von Yvonne Genzel
Alle Typen
Poster (139)
281.
Poster
Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
282.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
283.
Poster
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8th European Congress of Virology, Gdańsk (Poland) (2023)
284.
Poster
Absolute quantification of viral proteins during single-round replication of vaccine producer cell lines. 32nd Annual Meeting of the Society for Virology (GfV) , Ulm (Germany) (2023)
285.
Poster
Absolute quantification of influenza A virus proteins during single-round replication in vaccine producer cell lines. 16th PEACe (Protein Expression in Animal Cells) Conference, Sitges (Spain) (2023)
286.
Poster
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
287.
Poster
A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)
288.
Poster
Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral Efficacy. 32nd Annual Meeting of the Society for Virology (GFV), Ulm (Germany) (2023)
289.
Poster
Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processes. Vaccine Technology VIII, Sitges (Spain) (2022)
290.
Poster
Towards the production of a fusogenic oncolytic rVSV-NDV virus in perfusion mode. 27th ESACT Meeting, Lisbon (Portugal) (2022)
291.
Poster
Production of a fusogenic oncolytic VSV-NDV virus: cell-line screening and process development in small-scale suspension cultures. Advancing Manufacture of Cell and Gene Therapies VII, Coronado, CA (USA) (2022)
292.
Poster
Production of influenza A virus-derived defective interfering particles for antiviral therapy in a high cell density perfusion cultivation. 27th ESACT Meeting, Lisbon (Portugal) (2022)
293.
Poster
Absolute quantification of viral proteins during single-round replication of MDCK suspension cells. Proteomic Forum 2022, Leipzig (Germany) (2022)
294.
Poster
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
295.
Poster
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
296.
Poster
Generation and screening of monoclonal suspension MDCK cells for high-yield influenza A virus production. 3rd ESACT Frontiers Retreat, Vienna, Austria (2022)
297.
Poster
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
298.
Poster
Suspension MDCK cell line development by automated single-cell cloning & scale-down into ambr®15 microbioreactors in chemically defined medium. 27th ESACT Meeting, Lisbon (Portugal) (2022)
299.
Poster
Semi-continuous propagation of influenza A virus and its defective interfering particles - analyzing the dynamic competition to select antiviral candidates. 30th Annual Meeting of the Society for Virology, online (2021)
300.
Poster
Comprehensive N-glycosylation analysis of influenza A virus antigens derived from different production cell lines reveal immunogenic glycan epitopes. GlycoBioTec 2019, Berlin, Germany (2019)